title: Withdrawal of mycophenolate mofetil in stable renal transplant recipients.
abstract: BACKGROUND
  Mycophenolate mofetil (MMF) has been demonstrated to decrease episodes of acute rejection in renal transplant recipients during the first year after transplantation. The utility of MMF after 1 year is less clear.
  
  
  METHODS
  Forty-five stable renal transplant recipients on maintenance therapy of cyclosporine microemulsion, MMF, and prednisone had MMF withdrawn at approximately 1 year after transplantation. A matching concurrent group of 45 stable renal transplant recipients served as the case control group.
  
  
  RESULTS
  Two of 45 patients in the MMF withdrawal group suffered an acute rejection episode as opposed to 1 of 45 in the control group. Both patients who rejected in the withdrawal group had adequate cyclosporine levels and had no recent decrease in prednisone dose. There was no evidence of an increased incidence of proteinuria or increased creatinine levels in the MMF withdrawal group.
  
  
  CONCLUSIONS
  In general, withdrawal of MMF in stable renal transplant recipients is well tolerated. No increased risk of rejection could be demonstrated in this patient group. A larger study will be needed to confirm our result.
authors.affiliation: Department of Transplantation, Saint Barnabas Medical Center, Livingston, New Jersey 07039, USA. lbaker-williams@sbhcs.com
authors.forename: B
authors.initials: B
authors.lastname: Kaplan
authors.forename: H U
authors.initials: HU
authors.lastname: Meier-Kriesche
authors.forename: M
authors.initials: M
authors.lastname: Vaghela
authors.forename: G
authors.initials: G
authors.lastname: Friedman
authors.forename: S
authors.initials: S
authors.lastname: Mulgaonkar
authors.forename: M
authors.initials: M
authors.lastname: Jacobs
mesh_terms: D000328:Adult; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D011239:Prednisolone; D009173:Mycophenolic Acid